Research Solutions
RSSS
#9562
Rank
$77.65 M
Marketcap
$2.36
Share price
4.42%
Change (1 day)
-9.23%
Change (1 year)

Research Solutions - 10-Q quarterly report FY2020 Q1


Text size:

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2019

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission File No. 000-53501

 

RESEARCH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada11-3797644
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
  
16350 Ventura Blvd., Suite D #811, Encino, California91436
(Address of principal executive offices)(Zip Code)

 

(310) 477-0354

(Registrant’s telephone number, including area code)

 

15821 Ventura Blvd., Suite 165, Encino, California

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þNo ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes þ No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨Accelerated filer ¨
Non-accelerated filer þSmaller reporting company þ
 Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨No þ

  

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

 

Title of Class Number of Shares Outstanding on November 8, 2019
Common Stock, $0.001 par value  

24,488,035

 

 

  

 

 

 

TABLE OF CONTENTS

 

PART I — FINANCIAL INFORMATION3
Item 1. Condensed Consolidated Financial Statements (unaudited)3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations16
Item 3. Quantitative and Qualitative Disclosures About Market Risk23
Item 4. Controls and Procedures23
  
PART II — OTHER INFORMATION24
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds24
Item 6. Exhibits24
  
SIGNATURES25

 

2

 

 

PART 1 — FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Financial Statements

 

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

 

  September 30,    
  2019  June 30, 
  (unaudited)  2019 
Assets        
Current assets:        
Cash and cash equivalents $5,587,833  $5,353,090 
Accounts receivable, net of allowance of $100,110 and $100,175, respectively  4,376,807   4,493,169 
Prepaid expenses and other current assets  259,880   323,591 
Prepaid royalties  69,699   - 
Total current assets  10,294,219   10,169,850 
         
Other assets:        
Property and equipment, net of accumulated depreciation of $796,199 and $789,788, respectively  28,840   36,828 
Deposits and other assets  14,382   14,406 
Right of use asset, net of accumulated amortization of $300,290 and $270,777, respectively  162,732   192,245 
Total assets $10,500,173  $10,413,329 
         
Liabilities and Stockholders’ Equity        
Current liabilities:        
Accounts payable and accrued expenses $4,886,724  $4,862,895 
Deferred revenue  2,418,795   2,310,206 
Lease liability, current portion  131,617   129,187 
Total current liabilities  7,437,136   7,302,288 
         
Long-term liabilities:        
Lease liability, long-term portion  45,550   79,326 
Total liabilities  7,482,686   7,381,614 
         
Commitments and contingencies        
         
Stockholders’ equity:        
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding  -   - 
Common stock; $0.001 par value; 100,000,000 shares authorized; 24,441,505 and 24,375,948  shares issued and outstanding, respectively  24,442   24,376 
Additional paid-in capital  23,702,212   23,631,481 
Accumulated deficit  (20,596,014)  (20,514,557)
Accumulated other comprehensive loss  (113,153)  (109,585)
Total stockholders’ equity  3,017,487   3,031,715 
Total liabilities and stockholders’ equity $10,500,173  $10,413,329 

 

See notes to condensed consolidated financial statements

 

3

 

 

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(Unaudited)

 

  Three Months Ended 
  September 30, 
  2019  2018 
Revenue:        
Platforms $856,445  $589,013 
Transactions  6,738,668   6,363,508 
Total revenue  7,595,113   6,952,521 
         
Cost of revenue:        
Platforms  150,470   108,259 
Transactions  5,128,108   4,896,307 
Total cost of revenue  5,278,578   5,004,566 
Gross profit  2,316,535   1,947,955 
         
Operating expenses:        
Selling, general and administrative  2,435,680   2,170,712 
Depreciation and amortization  7,558   11,115 
Total operating expenses  2,443,238   2,181,827 
Loss from operations  (126,703)  (233,872)
         
Other income (expenses):        
Other income  25,549   23,485 
Total other income  25,549   23,485 
         
Loss from operations before provision for income taxes  (101,154)  (210,387)
Provision for income taxes  (6,494)  (9,221)
         
Loss from continuing operations  (107,648)  (219,608)
         
Gain from sale of discontinued operations  26,191   41,720 
         
Net loss  (81,457)  (177,888)
         
Other comprehensive loss:        
Foreign currency translation  (3,568)  (4,370)
Comprehensive loss $(85,025) $(182,258)
         
Loss per common share:        
Loss per share from continuing operations, basic and diluted $-  $(0.01)
Income per share from discontinued operations, basic and diluted $-  $- 
Net loss per share, basic and diluted $-  $(0.01)
Weighted average common shares outstanding, basic and diluted  24,095,266   23,644,787 

 

See notes to condensed consolidated financial statements

 

4

 

 

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statement of Stockholders' Equity

For the Three Months Ended September 30, 2019

(Unaudited)

 

  Common Stock  Additional Paid-in  Accumulated  Other Comprehensive  Total Stockholders' 
  Shares  Amount  Capital  Deficit  Loss  Equity 
                   
Balance, July 1, 2019  24,375,948  $24,376  $23,631,481  $(20,514,557) $(109,585) $3,031,715 
                         
Fair value of vested stock options  -   -   58,198   -   -   58,198 
                         
Fair value of vested restricted common stock  70,000   70   84,404   -   -   84,474 
                         
Repurchase of common stock  (28,750)  (28)  (71,847)  -   -   (71,875)
                         
Common stock issued upon exercise of stock options  24,307   24   (24)  -   -   - 
                         
Net loss for the period  -   -   -   (81,457)  -   (81,457)
                         
Foreign currency translation  -   -   -   -   (3,568)  (3,568)
                         
Balance, September 30, 2019  24,441,505  $24,442  $23,702,212  $(20,596,014) $(113,153) $3,017,487 

 

See notes to condensed consolidated financial statements

 

5

 

 

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statement of Stockholders' Equity

For the Three Months Ended September 30, 2018

(Unaudited)

 

  Common Stock  Additional Paid-in  Accumulated  Other Comprehensive  Total Stockholders' 
  Shares  Amount  Capital  Deficit  Loss  Equity 
Balance, July 1, 2018  24,016,999  $24,017  $22,904,691  $(19,554,599) $(94,707) $3,279,402 
                         
Fair value of vested stock options  -   -   39,648   -   -   39,648 
                         
Fair value of vested restricted common stock  130,127   130   76,131   -   -   76,261 
                         
Repurchase of common stock  (34,200)  (34)  (75,166)  -   -   (75,200)
                         
Common stock issued upon exercise of stock options  3,750   4   (4)  -   -   - 
                         
Common stock issued upon exercise of warrants  39,000   39   (39)  -   -   - 
                         
Net loss for the period  -   -   -   (177,888)  -   (177,888)
                         
Foreign currency translation  -   -   -   -   (4,370)  (4,370)
                         
Balance, September 30, 2018  24,155,676  $24,156  $22,945,261  $(19,732,487) $(99,077) $3,137,853 

 

See notes to condensed consolidated financial statements

 

6

 

 

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

  Three Months Ended 
  September 30, 
  2019  2018 
Cash flow from operating activities:        
Net loss $(81,457) $(177,888)
Adjustment to reconcile net loss to net cash provided by (used in) operating activities:        
Gain from sale of discontinued operations  (26,191)  (41,720)
Depreciation and amortization  7,558   11,115 
Amortization of lease right  29,513   28,338 
Fair value of vested stock options  58,198   39,648 
Fair value of vested restricted common stock  84,474   76,261 
Changes in operating assets and liabilities:        
Accounts receivable  116,362   200,015 
Prepaid expenses and other current assets  89,902   105,843 
Prepaid royalties  (69,699)  (162,067)
Accounts payable and accrued expenses  23,829   (320,404)
Deferred revenue  108,589   (30,219)
Lease liability  (31,346)  (29,045)
Net cash provided by (used in) operating activities  309,732   (300,123)
         
Cash flow from investing activities:        
Purchase of property and equipment  -   - 
Net cash used in investing activities  -   - 
         
Cash flow from financing activities:        
Common stock repurchase and retirement  (71,875)  (75,200)
Net cash used in financing activities  (71,875)  (75,200)
         
Effect of exchange rate changes  (3,114)  (5,830)
Net increase (decrease) in cash and cash equivalents  234,743   (381,153)
Cash and cash equivalents, beginning of period  5,353,090   4,908,180 
Cash and cash equivalents, end of period $5,587,833  $4,527,027 
         
Supplemental disclosures of cash flow information:        
Cash paid for income taxes $6,494  $9,221 

 

See notes to condensed consolidated financial statements 

 

7

 

 

RESEARCH SOLUTIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Three Months Ended September 30, 2019 and 2018 (Unaudited)

 

Note 1. Organization, Nature of Business and Basis of Presentation

 

Organization

 

Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with two wholly owned subsidiaries: Reprints Desk, Inc., a Delaware corporation and Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico.

 

Nature of Business

 

We provide two service offerings to our customers: annual licenses that allow customers to access and utilize certain premium features of our cloud based software-as-a-service (“SaaS”) research intelligence platform (“Platforms”) and the transactional sale of published scientific, technical, and medical (“STM”) content managed, sourced and delivered through the Platform (“Transactions”). Platforms and Transactions are packaged as a single solution that enable life science and other research intensive organizations to speed up research and development activities with faster, single sourced access and management of content and data used throughout the intellectual property development lifecycle.

 

Platforms

 

Our cloud-based SaaS research intelligence platform consists of proprietary software and Internet-based interfaces sold to customers for an annual subscription fee. Legacy functionality allows customers to initiate orders, route orders for the lowest cost acquisition, manage transactions, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. Customers can also enhance the information resources they already own or license and collaborate around bibliographic information.

 

Additional functionality has recently been added to our Platform in the form of interactive app-like gadgets. An alternative to manual data filtering, identification and extraction, gadgets are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We are rapidly developing new gadgets in order to build an ecosystem of gadgets. Together, these gadgets will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes.

 

Our Platform is deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform’s efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage.

 

Transactions

 

Our Platform provides our customers with a single source to the universe of published STM content that includes over 70 million existing STM articles and over one million newly published STM articles each year. STM content is sold to our customers on a transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users.

 

Our Platform allows customers to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes.

 

Principles of Consolidation

 

The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

 

8

 

  

Basis of Presentation

 

The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2019 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

 

Note 2. Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.

 

These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets.

 

Concentration of Credit Risk

 

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer's financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer's financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required.

 

Cash denominated in Euros with a US Dollar equivalent of $109,105 and $63,933 at September 30, 2019 and June 30, 2019, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe.

 

The Company has no customers that represent 10% of revenue or more for the three months ended September 30, 2019 and 2018.

 

The following table summarizes accounts receivable concentrations:

 

  As of 
  September 30,  June 30, 
  2019  2019 
Customer A  13%  * 

 

* Less than 10%

 

The following table summarizes vendor concentrations:

 

  

Three Months Ended

September 30,

 
  2019  2018 
Vendor A  20%  18%
Vendor B  12%  11%
Vendor C  *   11%

 

 

* Less than 10%

 

9

 

 

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. The Company adopted the guidance of ASC 606 on July 1, 2018. The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

 

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

 

 

 

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

 

 identify the contract with a customer;
 identify the performance obligations in the contract;
 determine the transaction price;
 allocate the transaction price to performance obligations in the contract; and
 recognize revenue as the performance obligation is satisfied.

 

Platforms

 

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

 

Transactions

 

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

 

Deferred Revenue

 

Customer deposits and billings or payments received in advance of revenue recognition are recorded as deferred revenue.

 

Cost of Revenue

 

Platforms

 

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

 

Transactions

 

Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.

 

10

 

 

Stock-Based Compensation

 

The Company periodically issues stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company estimates the fair value of restricted stock awards to employees and directors using the market price of the Company’s common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company's Statements of Operations. The Company accounts for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. 

 

Foreign Currency

 

The accompanying consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities.

 

Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to a loss of $12,123 and $4,980, for the three months ended September 30, 2019 and 2018, respectively. Cash denominated in Euros with a US Dollar equivalent of $109,105 and $63,933 at September 30, 2019 and June 30, 2019, respectively, was held in accounts at financial institutions located in Europe.

 

The following table summarizes the exchange rates used:

 

  Three Months Ended
September 30,
  Year Ended
June 30,
 
  2019  2018  2019  2018 
Period end Euro : US Dollar exchange rate  1.09   1.16   1.14   1.17 
Average period Euro : US Dollar exchange rate  1.12   1.16   1.14   1.19 
                 
Period end Mexican Peso : US Dollar exchange rate  0.05   0.05   0.05   0.05 
Average period Mexican Peso : US Dollar exchange rate  0.05   0.05   0.05   0.05 

 

Net Income (Loss) Per Share

 

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stock holders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At September 30, 2019 potentially dilutive securities include options to acquire 3,297,335 shares of common stock, warrants to acquire 1,885,000 shares of common stock and unvested restricted common stock of 292,283.  At September 30, 2018 potentially dilutive securities include options to acquire 3,271,835 shares of common stock, warrants to acquire 1,885,000 shares of common stock and unvested restricted common stock of 434,781. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

 

Basic and diluted net loss per common share is the same for the three months ended September 30, 2019 and 2018 because all stock options, warrants, and unvested restricted common stock are anti-dilutive.

  

Recently Issued Accounting Pronouncements

 

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 amends certain disclosure requirements pertaining to fair value measurement, and is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of ASU 2018-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows.

 

11

 

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. 

 

Note 3. Line of Credit

 

The Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on December 31, 2019, and is subject to certain financial and performance covenants with which we were in compliance as of September 30, 2019. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0, and maintaining tangible net worth of $1,500,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2017, plus 50% of the dollar value of equity issuances after October 1, 2017 and the principal amount of subordinated debt. The line of credit bears interest at the prime rate plus 2.25% for periods in which we maintain an adjusted quick ratio of 1.3 to 1.0 (the “Streamline Period”), and at the prime rate plus 5.25% when a Streamline Period is not in effect. The interest rate on the line of credit was 6.75% as of September 30, 2019. The line of credit is secured by the Company’s consolidated assets.

 

There were no outstanding borrowings under the line as of September 30, 2019 and June 30, 2019, respectively.  As of September 30, 2019, there was approximately $2,153,000 of available credit.

 

Note 4. Lease Obligations

 

On December 30, 2016, the Company entered into a 48 month non-cancellable lease for its office facilities that will require monthly payments ranging from $10,350 to $11,475 through January 2021. In accounting for the lease, the Company adopted ASU 2016-02, Leases which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the fair value of the lease assets and liability at the inception of the lease was $463,000 using a discount rate of 3.75%. During the three months ended September 30, 2019, the Company made payments of $31,346 towards the lease liability. As of September 30, 2019 and June 30, 2019, lease liability amounted to $177,167 and $208,513, respectively. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense, including real estate taxes, for the three months ended September 30, 2019 and 2018 was $37,122 and $36,212, respectively. The right of use asset at June 30, 2019 was $192,245. During the three months ended September 30, 2019, the Company reflected amortization of right of use asset of $29,513 related to this lease, resulting in a net asset balance of $162,732 as of September 30, 2019.

 

Note 5. Stockholders’ Equity

 

Stock Options

 

In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the 2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of September 30, 2019, there were 417,246 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan.

 

The majority of awards issued under the Plan vest immediately or over three years, with a one year cliff vesting period, and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period.

 

The following table summarizes vested and unvested stock option activity:

 

  All Options  Vested Options  Unvested Options 
  Shares  

Weighted

Average

Exercise

Price

  Shares  

Weighted

Average

Exercise

Price

  Shares  

Weighted

Average

Exercise

Price

 
Outstanding at June 30, 2019  3,287,335  $1.38   2,827,251  $1.27   460,084  $2.09 
Granted  50,000   2.49   -   -   50,000   2.49 
Options vesting  -   -   99,083   1.90   (99,083)  1.90 
Exercised  (40,000)  1.02   (40,000)  1.02   -   - 
Forfeited/Cancelled  -   -   -   -   -   - 
Outstanding at September 30, 2019  3,297,335  $1.41   2,886,334  $1.30   411,001  $2.18 

 

12

 

   

The weighted average remaining contractual life of all options outstanding as of September 30, 2019 was 5.98 years. The remaining contractual life for options vested and exercisable at September 30, 2019 was 5.54 years. Furthermore, the aggregate intrinsic value of options outstanding as of September 30, 2019 was $3,447,191, and the aggregate intrinsic value of options vested and exercisable at September 30, 2019 was $3,333,292, in each case based on the fair value of the Company’s common stock on September 30, 2019.

 

During the three months ended September 30, 2019, the Company granted 50,000 options to employees with a fair value of $65,500. The total fair value of options that vested during the three months ended September 30, 2019 was $58,198 and is included in selling, general and administrative expenses in the accompanying statement of operations. As of September 30, 2019, the amount of unvested compensation related to stock options was $433,203 which will be recorded as an expense in future periods as the options vest. During the three months ended September 30, 2019, the Company issued 24,307 shares of common stock upon the exercise of 40,000 options on a cashless basis.

 

The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the three months ended September 30, 2019 and 2018.

 

  

Three Months Ended

September 30,

 
  2019  2018 
Expected dividend yield  0%  0%
Risk-free interest rate  1.61%  2.82%
Expected life (in years)  6   6 
Expected volatility  64%  68%

 

Additional information regarding stock options outstanding and exercisable as of September 30, 2019 is as follows:

 

Option
Exercise
Price
  Options
Outstanding
  

Remaining 

Contractual 

Life (in years)

  Options
Exercisable
 
$0.59   8,150   2.75   8,150 
 0.60   5,000   2.75   5,000 
 0.65   6,150   2.75   6,150 
 0.70   225,000   6.18   225,000 
 0.77   59,500   4.01   59,500 
 0.80   16,000   5.89   16,000 
 0.90   25,667   4.56   25,667 
 0.97   6,000   2.75   6,000 
 1.00   28,249   4.18   28,249 
 1.02   187,000   0.85   187,000 
 1.05   422,529   6.86   422,529 
 1.07   53,898   3.04   53,898 
 1.09   151,165   6.19   151,165 
 1.10   105,000   5.75   105,000 
 1.14   3,674   2.75   3,674 
 1.15   209,400   4.86   209,400 
 1.20   352,414   7.83   345,080 
 1.25   32,000   3.38   32,000 
 1.30   243,000   2.43   243,000 
 1.50   195,000   3.13   195,000 
 1.59   35,000   8.62   17,500 
 1.75   1,067   2.75   1,067 
 1.80   134,050   3.64   134,050 
 1.85   24,000   3.34   24,000 
 1.95   295,000   8.76   130,833 
 1.97   1,422   2.75   1,422 
 2.40   402,000   9.13   250,000 
 2.49   50,000   10.00   - 
 2.50   20,000   9.64   - 
 Total   3,297,335       2,886,334 

 

13

 

 

Warrants

 

The following table summarizes warrant activity:

 

  

Number of

Warrants

  

Weighted

Average

Exercise

Price

 
Outstanding, June 30, 2019  1,885,000  $1.25 
Granted  -   - 
Exercised  -   - 
Expired/Cancelled  -   - 
Outstanding, September 30, 2019  1,885,000  $1.25 
Exercisable, June 30, 2019  1,885,000  $1.25 
Exercisable, September 30, 2019  1,885,000  $1.25 

 

The intrinsic value for all warrants outstanding as of September 30, 2019 was $2,265,500, based on the fair value of the Company’s common stock on September 30, 2019.

 

Additional information regarding warrants outstanding and exercisable as of September 30, 2019 is as follows:

 

Warrant
Exercise Price
  

Warrants

Outstanding

  

Remaining 

Contractual 

Life (in years)

  Warrants
Exercisable
 
$1.19   50,000   2.23   50,000 
 1.25   1,835,000   1.71   1,835,000 
 Total   1,885,000       1,885,000 

 

Restricted Common Stock

 

Prior to July 1, 2019, the Company issued 2,166,549 shares of restricted common stock to employees valued at $2,386,443, of which 1,640,690 shares have vested, 214,324 shares with fair value of $188,203 have been forfeited, and $1,785,857 has been recognized as an expense. The balance of the non-vested restricted common stock was 311,535 at June 30, 2019.

 

During the three months ended September 30, 2019, the Company issued an additional 70,000 shares of restricted stock to employees. These shares vest over a three year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock awards was $192,500 based on the market price of our common stock price of $2.75 per share on the date of grant, which will be amortized over the three-year vesting period.

 

The total fair value of restricted common stock vesting during the nine months ended September 30, 2019 was $84,473 and is included in selling, general and administrative expenses in the accompanying statements of operations. As of September 30, 2019, the amount of unvested compensation related to issuances of restricted common stock was $520,410, which will be recognized as an expense in future periods as the shares vest. When calculating basic net income (loss) per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date.

 

14

 

 

The following table summarizes restricted common stock activity:

 

  

Number of

Shares

  Fair Value  

Weighted

Average

Grant Date

Fair Value

 
Non-vested, June 30, 2019  311,535  $412,383  $1.66 
Granted  70,000   192,500   2.75 
Vested  (89,252)  (84,473)  1.64 
Forfeited  -   -   - 
Non-vested, September 30, 2019  292,283  $520,410  $1.93 

 

Common Stock Repurchase and Retirement

 

Effective as of November 13, 2018, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2019 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $300,000 of outstanding common stock (at prices no greater than $3.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors.

 

During the three months ended September 30, 2019, the Company repurchased 28,750 shares of our common stock from employees at an average market price of approximately $2.50 per share for an aggregate amount of $71,875.

 

As of September 30, 2019, $141,380 remains available under the 2019 plan to repurchase common stock from its employees. The shares of common stock were surrendered by employees to cover tax withholding obligations with respect to the vesting of restricted stock. Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value.

 

Note 6.  Gain from Sale of Discontinued Operations (Reprints and ePrints business line)

 

On June 30, 2017, we sold the intangible assets of our Reprints and ePrints business pursuant to an Asset Purchase Agreement dated June 20, 2017. The aggregate net consideration for the sale included earn-out payments of 45% of gross margin over the 30-month period subsequent to the closing date. We have made a policy election to record the contingent consideration when the consideration is determined to be realizable (each 6-month period ending subsequent to the closing date). Realizable contingent consideration amounted to $26,191 for the three months ended September 30, 2019 and is recorded as a gain from the sale of discontinued operations. 

 

Note 7.  Subsequent Events

 

On October 8, 2019, the Company entered into an agreement to sublease its office facilities from November 1, 2019 through January 31, 2021, the end of the lease term, for $8,094 per month with one month of abated rent.

 

On October 24, 2019, the Company issued 8,701 net shares of common stock upon the exercise of stock options underlying 31,422 shares of common stock for 22,721 shares of common stock.

 

On November 5, 2019, the Company issued 37,829 shares of common stock upon the exercise of stock options underlying 60,00 shares of common stock on a cashless basis.

 

On November 12, 2019, the Company’s stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 1,874,513 to 2,874,513.

  

15

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Notice Regarding Forward-Looking Statements

 

The following discussion and analysis of our financial condition and results of operations for the three months ended September 30, 2019 and 2018 should be read in conjunction with our consolidated financial statements and related notes to those financial statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019.

 

We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. All forward-looking statements included in this report are based on information available to us on the date hereof and, except as required by law, we assume no obligation to update any such forward-looking statements.

 

Overview

 

Research Solutions was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with two wholly owned subsidiaries at June 30, 2019: Reprints Desk, Inc., a Delaware corporation and Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico.

 

We provide two service offerings to our customers: annual licenses that allow customers to access and utilize certain premium features of our cloud based software-as-a-service (“SaaS”) research intelligence platform (“Platforms”) and the transactional sale of published scientific, technical, and medical (“STM”) content managed, sourced and delivered through the Platform (“Transactions”). Platforms and Transactions are packaged as a single solution that enable life science and other research intensive organizations to speed up research and development activities with faster, single sourced access and management of content and data used throughout the intellectual property development lifecycle.

 

Platforms

 

Our cloud-based SaaS research intelligence platform consists of proprietary software and Internet-based interfaces sold to customers for an annual subscription fee. Legacy functionality allows customers to initiate orders, route orders for the lowest cost acquisition, manage transactions, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. Customers can also enhance the information resources they already own or license and collaborate around bibliographic information.

 

Additional functionality has recently been added to our Platform in the form of interactive app-like gadgets. An alternative to manual data filtering, identification and extraction, gadgets are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We are rapidly developing new gadgets in order to build an ecosystem of gadgets. Together, these gadgets will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes.

 

Our Platform is deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform’s efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage.

 

Transactions

 

Our Platform provides our customers with a single source to the universe of published STM content that includes over 70 million existing STM articles and over one million newly published STM articles each year. STM content is sold to our customers on a transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users.

 

Our Platform allows customers to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes.

 

16

 

 

Critical Accounting Policies and Estimates

 

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may differ under different estimates and assumptions.

 

The accounting estimates and assumptions discussed in this section are those that we consider to be the most critical to an understanding of our financial statements because they inherently involve significant judgments and uncertainties.

 

Revenue Recognition

 

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. We adopted the guidance of ASC 606 on July 1, 2018. The implementation of ASC 606 had no impact on the condensed consolidated financial statements and no cumulative effect adjustment was recognized.

 

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We derive our revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

 

 

 

We apply the following five steps in order to determine the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements:

 

 identify the contract with a customer;
 identify the performance obligations in the contract;
 determine the transaction price;
 allocate the transaction price to performance obligations in the contract; and
 recognize revenue as the performance obligation is satisfied.

 

Platforms

 

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

 

Transactions

 

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

 

Stock-Based Compensation

 

We periodically issue stock options, warrants and restricted stock to employees and non-employees for services, in capital raising transactions, and for financing costs. We account for share-based payments under the guidance as set forth in the Share-Based Payment Topic 718 of the FASB Accounting Standards Codification, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We account for share-based payments to non-employees in accordance with Topic 505 of the FASB Accounting Standards Codification, whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. 

 

17

 

 

Recent Accounting Pronouncements

 

Please refer to footnote 2 to the condensed consolidated financial statements contained elsewhere in this Form 10-Q for a discussion of Recent Accounting Pronouncements.

 

Quarterly Information (Unaudited)

 

The following table sets forth unaudited and quarterly financial data for the most recent eight quarters:

 

  Sept. 30,  June 30,  Mar. 31,  Dec. 31,  Sept. 30,  June 30,  Mar. 31,  Dec. 31, 
  2019  2019  2019  2018  2018  2018  2018  2017 
Revenue:                                
Platforms $856,445  $803,917  $748,726  $667,545  $589,013  $528,581  $489,219  $413,404 
Transactions  6,738,668   6,670,685   6,629,231   6,321,297   6,363,508   6,637,292   6,792,289   6,409,816 
Total revenue  7,595,113   7,474,602   7,377,957   6,988,842   6,952,521   7,165,873   7,281,508   6,823,220 
                                 
Cost of revenue:                                
Platforms  150,470   142,368   134,672   122,077   108,259   101,370   103,185   90,362 
Transactions  5,128,108   5,104,629   5,063,624   4,878,526   4,896,307   5,118,851   5,259,959   4,996,988 
Total cost of revenue  5,278,578   5,246,997   5,198,296   5,000,603   5,004,566   5,220,221   5,363,144   5,087,350 
                                 
Gross profit:                                
Platforms  705,975   661,549   614,054   545,468   480,754   427,211   386,034   323,042 
Transactions  1,610,560   1,566,056   1,565,607   1,442,771   1,467,201   1,518,441   1,532,330   1,412,828 
Total gross profit  2,316,535   2,227,605   2,179,661   1,988,239   1,947,955   1,945,652   1,918,364   1,735,870 
                                 
Operating expenses:                                
Sales and marketing  550,349   659,108   542,641   445,879   431,417   455,250   522,894   524,587 
Technology and product dev.  499,191   549,198   537,685   553,272   499,795   454,053   436,672   454,507 
General and administrative  1,231,345   1,060,269   1,129,461   1,180,599   1,118,611   1,062,981   1,091,928   1,098,795 
Depreciation and amortization  7,558   8,351   9,617   9,733   11,115   32,731   32,768   46,330 
Stock-based comp. expense  142,672   126,903   131,072   453,288   115,909   75,089   114,340   314,565 
Foreign currency transaction loss (gain)  12,123   7,193   2,302   10,025   4,980   14,589   (9,737)  (485)
Total operating expenses  2,443,238   2,411,022   2,352,778   2,652,796   2,181,827   2,094,693   2,188,865   2,438,299 
Other income (expenses and income taxes)  19,055   27,289   22,393   16,322   14,264   12,615   5,238   (1,504)
Loss from continuing operations  (107,648)  (156,128)  (150,724)  (648,235)  (219,608)  (136,426)  (265,263)  (703,933)
Gain on sale of discontinued operations  26,191   84,275   33,044   55,698   41,720   51,216   69,277   79,353 
Net income (loss)  (81,457)  (71,853)  (117,680)  (592,537)  (177,888)  (85,210)  (195,986)  (624,580)
                                 
Basic income (loss) per common share:                                
Loss per share from continuing operations $ -  $ -  $ -  $ (0.03) $ (0.01) $ (0.01) $ (0.01) $ (0.03)
Income per share from discontinued operations $ -  $ -  $ -  $ -  $ -  $ -  $ -  $ - 
Net income (loss) per share $ -  $ -  $ -  $ (0.03) $ (0.01) $ (0.01) $ (0.01) $ (0.03)
Basic weighted average common shares outstanding  24,095,266   23,987,137   23,845,798   23,787,836   23,644,787   23,560,781   23,498,796   23,455,654 
                                 
Diluted income (loss) per common share:                                
Loss per share from continuing operations $ -  $ -  $ -  $ (0.03) $ (0.01) $ (0.01) $ (0.01) $ (0.03)
Income per share from discontinued operations $ -  $ -  $ -  $ -  $ -  $ -  $ -  $ - 
Net income (loss) per share $ -  $ -  $ -  $ (0.03) $ (0.01) $ (0.01) $ (0.01) $ (0.03)
Diluted weighted average common shares outstanding  24,095,266   23,987,137   23,845,798   23,787,836   23,644,787   23,560,781   23,498,796   23,455,654 

 

18

 

 

Comparison of the Three Months Ended September 30, 2019 and 2018

 

Results of Operations

 

  Three Months Ended September 30, 
  2019  2018  2019-2018
$ Change
  2019-2018
% Change
 
Revenue:                
Platforms $856,445  $589,013  $267,432   45.4%
Transactions  6,738,668   6,363,508   375,160   5.9%
Total revenue  7,595,113   6,952,521   642,592   9.2%
                 
Cost of revenue:                
Platforms  150,470   108,259   42,211   39.0%
Transactions  5,128,108   4,896,307   231,801   4.7%
Total cost of revenue  5,278,578   5,004,566   274,012   5.5%
                 
Gross profit:                
Platforms  705,975   480,754   225,221   46.8%
Transactions  1,610,560   1,467,201   143,359   9.8%
Total gross profit  2,316,535   1,947,955   368,580   18.9%
                 
Operating expenses:                
Sales and marketing  550,349   431,417   118,932   27.6%
Technology and product development  499,191   499,795   (604)  (0.1)%
General and administrative  1,231,345   1,118,611   112,734   10.1%
Depreciation and amortization  7,558   11,115   (3,557)  (32.0)%
Stock-based compensation expense  142,672   115,909   26,763   23.1%
Foreign currency transaction loss (gain)  12,123   4,980   7,143   143.4%
Total operating expenses  2,443,238   2,181,827   261,411   12.0%
Loss from operations  (126,703)  (233,872)  107,169   45.8%
                 
Other income (expenses):                
Other income  25,549   23,485   2,064   8.8%
Total other income  25,549   23,485   2,064   8.8%
                 
Loss from operations before provision for income taxes  (101,154)  (210,387)  109,233   51.9%
Provision for income taxes  (6,494)  (9,221)  2,727   29.6%
                 
Loss from continuing operations  (107,648)  (219,608)  111,960   51.0%
                 
Gain from sale of discontinued operations  26,191   41,720   (15,529)  (37.2)%
                 
Net loss $(81,457) $(177,888) $96,431   54.2%

 

Revenue

 

  Three Months Ended September 30, 
  2019  2018  

2019-2018

$ Change

  

2019-2018

% Change

 
Revenue:            
Platforms $856,445  $589,013  $267,432   45.4%
Transactions  6,738,668   6,363,508   375,160   5.9%
Total revenue $7,595,113  $6,952,521  $642,592   9.2%

 

19

 

 

Total revenue increased $642,592, or 1.3%, for the three months ended September 30, 2019 compared to the prior year, due to the following:

 

Category  Impact Key Drivers
Platforms  $ 267,432 Increased due to additional deployments to new and existing customers, and expansion from existing customers. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Transactions   $ 375,160  Increased primarily due to orders from new customers.

 

Cost of Revenue

 

  Three Months Ended September 30, 
  2019  2018  

2019-2018

$ Change

  

2019-2018

% Change

 
Cost of Revenue:            
Platforms $150,470  $108,259  $42,211   39.0%
Transactions  5,128,108   4,896,307   231,801   4.7%
Total cost of revenue $5,278,578  $5,004,566  $274,012   5.5%

 

  Three Months Ended September 30, 
  2019  2018  

2019-2018

Change *

 
As a percentage of revenue:         
Platforms  17.6%  18.4%  (0.8)%
Transactions  76.1%  76.9%  (0.8)%
Total  69.5%  72.0%  (2.5)%

 

* The difference between current and prior period cost of revenue as a percentage of revenue

  

Total cost of revenue as a percentage of revenue decreased 2.5%, from 72% for the previous year to 69.5%, for the three months ended September 30, 2019.

 

Category  Impact as percentage
of revenue
 Key Drivers
Platforms   0.8 % Decreased primarily due to proportionally lower third-party data costs.
Transactions    0.8 % Decreased primarily due to proportionally lower personnel and copyright costs.

 

Gross Profit

 

  Three Months Ended September 30, 
  2019  2018  

2019-2018

$ Change

  

2019-2018

% Change

 
Gross Profit:                
Platforms $705,975  $480,754  $225,221   46.8%
Transactions  1,610,560   1,467,201   143,359   9.8%
Total gross profit $2,316,535  $1,947,955  $368,580   18.9%

 

  Three Months Ended September 30, 
  2019  2018  

2019-2018

Change *

 
As a percentage of revenue:            
Platforms  82.4%  81.6%  0.8%
Transactions  23.9%  23.1%  0.8%
Total  30.5%  28.0%  2.5%

 

* The difference between current and prior period gross profit as a percentage of revenue

  

20

 

  

Operating Expenses

 

  Three Months Ended September 30, 
  2019  2018  

2019-2018

$ Change

  

2019-2018

% Change

 
Operating Expenses:                
Sales and marketing $550,349  $431,417  $118,932   27.6%
Technology and product development  499,191   499,795   (604)  (0.1)%
General and administrative  1,231,345   1,118,611   112,734   10.1%
Depreciation and amortization  7,558   11,115   (3,557)  (32.0)%
Stock-based compensation expense  142,672   115,909   26,763   23.1%
Foreign currency transaction loss (gain)  12,123   4,980   7,143   143.4%
Total operating expenses $2,443,238  $2,181,827  $261,411   12.0%

 

Category ImpactKey Drivers
Sales and marketing$118,932  Increased primarily due to greater advertising media spend.
General and administrative $ 112,734  Increased primarily due to greater professional service fees.

 

Net Income (Loss)

 

  Three Months Ended September 30, 
  2019  2018  

2019-2018

$ Change

  

2019-2018

% Change

 
Net Income (Loss):                
Loss from continuing operations $(107,648) $(219,608) $111,960   51.0%
Income from discontinued operations  26,191   41,720   (15,529)  (37.2)%
Total net loss $(81,457) $(177,888) $96,431   54.2%

 

Loss from continuing operations decreased $111,960 or 51%, for the three months ended September 30, 2019 compared to the prior year, primarily due to increased gross profit, partially offset by increased operating expenses as described above.

 

Liquidity and Capital Resources

 

  Three Months Ended September 30, 
Consolidated Statements of Cash Flow Data: 2019  2018 
Net cash provided by (used in) operating activities $309,732  $(300,123)
Net cash used in financing activities  (71,875)  (75,200)
         
Effect of exchange rate changes  (3,114)  (5,830)
Net increase (decrease) in cash and cash equivalents  234,743   (381,153)
Cash and cash equivalents, beginning of period  5,353,090   4,908,180 
Cash and cash equivalents, end of period $5,587,833  $4,527,027 

 

Liquidity

 

Since our inception, we have funded our operations primarily through private sales of equity securities and the exercise of warrants, which have provided aggregate net cash proceeds to date of approximately $15,972,000. As of September 30, 2019, we had working capital of $2,857,083 and stockholders’ equity of $3,017,487. For the three months ended September 30, 2019, we recorded a net loss of $81,457, and cash provided by operating activities was $309,732. We may incur losses for an indeterminate period and may never sustain profitability. We may be unable to achieve and maintain profitability on a quarterly or annual basis. An extended period of losses and negative cash flow may prevent us from successfully operating and expanding our business.

 

As of September 30, 2019, we had cash and cash equivalents of $5,587,833, compared to $5,353,090 as of June 30, 2019, an increase of $234,743. This increase was primarily due to cash provided by operating activities.

 

21

 

Operating Activities

 

Net cash provided by operating activities was $309,732 for the three months ended September 30, 2019 and resulted primarily from a decrease in accounts receivable of $116,362 and an increase in deferred revenue of $108,589, partially offset by an increase in prepaid royalties of $69,699.

 

Net cash used in operating activities was $300,123 for the three months ended September 30, 2018 and resulted primarily from a decrease in accounts payable and accrued expenses of $320,404 and an increase in prepaid royalties of $162,067, partially offset by a decrease in accounts receivable of $200,015.

 

Investing Activities

 

No cash was used in or provided by investing activities for the three months ended September 30, 2019 and 2018.

 

Financing Activities

 

Net cash used in financing activities was $71,875 for the three months ended September 30, 2019 and resulted from the repurchase of common stock.

 

Net cash used in financing activities was $75,200 for the three months ended September 30, 2018 and resulted from the repurchase of common stock.

 

We entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on December 31, 2019, and is subject to certain financial and performance covenants with which we were in compliance as of September 30, 2019. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0, and maintaining tangible net worth of $1,500,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2017, plus 50% of the dollar value of equity issuances after October 1, 2017 and the principal amount of subordinated debt. The line of credit bears interest at the prime rate plus 2.25% for periods in which we maintain an adjusted quick ratio of 1.3 to 1.0 (the “Streamline Period”), and at the prime rate plus 5.25% when a Streamline Period is not in effect. The interest rate on the line of credit was 6.75% as of September 30, 2019. The line of credit was secured by our consolidated assets.

 

There were no outstanding borrowings under the line as of September 30, 2019 and June 30, 2019, respectively.  As of September 30, 2019, there was approximately $2,153,000 of available credit.

 

Non-GAAP Measure – Adjusted EBITDA

 

In addition to our GAAP results, we present Adjusted EBITDA as a supplemental measure of our performance. However, Adjusted EBITDA is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations or any other performance measure derived in accordance with GAAP or as an alternative to cash flow from operating activities as a measure of liquidity. We define Adjusted EBITDA as net income (loss), plus interest expense, other income (expense), foreign currency transaction loss, provision for income taxes, depreciation and amortization, stock-based compensation, income from discontinued operations and gain on sale of discontinued operations. Management considers our core operating performance to be that which our managers can affect in any particular period through their management of the resources that affect our underlying revenue and profit generating operations that period. Non-GAAP adjustments to our results prepared in accordance with GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

 

Set forth below is a reconciliation of Adjusted EBITDA to net income (loss) for the three months ended September 30, 2019 and 2018:

 

  Three Months Ended September 30, 
  2019  2018  

2019-2018

$ Change

 
Net loss $(81,457) $(177,888) $96,431 
Add (deduct):            
Other (income) expense  (25,549)  (23,485)  (2,064)
Foreign currency transaction loss (gain)  12,123   4,980   7,143 
Provision for income taxes  6,494   9,221   (2,727)
Depreciation and amortization  7,558   11,115   (3,557)
Stock-based compensation  142,672   115,909   26,763 
Gain on sale of discontinued operations  (26,191)  (41,720)  15,529 
Adjusted EBITDA $35,650  $(101,868) $137,518 

 

22

 

 

We present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA in developing our internal budgets, forecasts and strategic plan; in analyzing the effectiveness of our business strategies in evaluating potential acquisitions; and in making compensation decisions and in communications with our board of directors concerning our financial performance. Adjusted EBITDA has limitations as an analytical tool, which includes, among others, the following:

 

 ·Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;

 

 ·Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

 

 ·Adjusted EBITDA does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; and

 

 ·although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not required.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. For purposes of this section, the term disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2019, the end of the period covered by this report, our disclosure controls and procedures were effective at a reasonable assurance level.

 

Inherent Limitations on the Effectiveness of Controls

 

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

 

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

Changes in Internal Control Over Financial Reporting

 

In addition, our management with the participation of our principal executive officer and principal financial officer have determined that no change in our internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Exchange Act) occurred during the quarter ended September 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

23

 

 

PART II — OTHER INFORMATION

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Effective as of November 13, 2018, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2019 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $300,000 of outstanding common stock (at prices no greater than $3.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors.

 

During the three months ended September 30, 2019, we repurchased 28,750 shares of our common stock from employees at an average market price of approximately $2.50 per share for an aggregate amount of $71,875.

 

As of September 30, 2019, $141,380 remains available under the 2019 plan to repurchase common stock from our employees. The shares of common stock were surrendered by employees to cover tax withholding obligations with respect to the vesting of restricted stock. Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value.

 

The following table summarizes repurchases of our common stock on a monthly basis:

  

Period Total Number
of Shares
Purchased
1
  Average
Price Paid per
Share
  Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs
  Approximate Dollar
Value of Shares that
May Yet Be
Purchased Under
the Plans or
Programs
 
July 2019  -   -   -  $213,255 
August 2019  -   -   -  $213,255 
September 2019  28,750  $2.50   -  $141,380 
Total  28,750  $2.50   -   - 

 

1 Consists of shares of common stock purchased from an employee to satisfy tax obligations in connection with the vesting of stock incentive awards.

  

Item 6. Exhibits

 

See “Exhibit Index” on the page immediately following the signature page hereto for a list of exhibits filed as part of this report, which is incorporated herein by reference.

 

24

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 RESEARCH SOLUTIONS, INC.
  
 By:/s/ Peter Victor Derycz
   
  Peter Victor Derycz
Date: November 14, 2019 Chief Executive Officer (Principal Executive Officer)
 
 By:/s/ Alan Louis Urban
   
  Alan Louis Urban
Date: November 14, 2019 Chief Financial Officer (Principal Financial and Accounting Officer)

 

25

 

 

EXHIBIT INDEX

 

Exhibit

Number

 Description
10.1 Consulting Agreement dated July 1, 2019, between Research Solutions, Inc. and Yohann Georgel. (Incorporated by reference to Exhibit 10.42 to the Registrant’s Annual Report on Form 10-K filed September 19, 2019.)++
31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1 Section 1350 Certification of Chief Executive Officer *
32.2 Section 1350 Certification of Chief Financial Officer *
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema
101.CAL XBRL Taxonomy Extension Calculation Linkbase
101.DEF XBRL Taxonomy Extension Definition Linkbase
101.LAB XBRL Taxonomy Extension Label Linkbase
101.PRE XBRL Taxonomy Extension Presentation Linkbase
 *Furnished herewith
 ++Indicates management contract or compensatory plan

 

  

26